MapLight Therapeutics, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses), averaging -58.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.40 | $-1.32 | +5.7% | Beat | |
| Q1 FY26 | $-0.91 | $-1.34 | -47.3% | Miss | |
| Q4 FY25 | $-1.05 | $-2.47 | -135.2% | Miss | |
| Q3 FY25 | not reported | $-37.18 | not reported | not reported |
Back to MPLT overview · MPLT holders · MPLT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.